Biology of CCR5 and its role in HIV infection and treatment

JAMA

Volumn 296, Issue 7, 2006, Pages 815-826

  Lederman, Michael M ^a,c   Penn Nicholson, Adam ^a   Cho, Michael ^a   Mosier, Donald ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; ENFUVIRTIDE; EOTAXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; PROTEIN HCC 1; PROTEIN HCC 4; RANTES; UNCLASSIFIED DRUG;

HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; LITERATURE; MEDLINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

EID: 33747132429     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.7.815     Document Type: Review

References (113)

1. Lederman MM. Host-directed and immune-based therapies for human immunodeficiency virus infection. Ann Intern Med. 1995;122:218-222.
2. Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust. 2005;183:205-208.
3. Ruderman EM, Pope RM. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther. 2005;7(suppl 2):S21-S25.
4. Hasler P. Biological therapies directed against cells in autoimmune disease. Springer Semin Immunopathol. 2006;27:443-456.
5. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15-23.
6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
7. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924-933.
8. Murphy PM. Chemokines. In: Paul WE, ed. Fundamental Immunology. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2003:801-840.
9. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 2000;289:739-745.
10. Howard OM, Shirakawa AK, Turpin JA, et al. Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 co-receptor and ligand binding function. J Biol Chem. 1999;274:16228-16234.
11. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004;16:1201-1210.
12. Aramori I, Ferguson SS, Bieniasz PD, Zhang J, Cullen B, Cullen MG. Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. EMBO J. 1997;16:4606-4616.
13. Zhao J, Ma L, Wu YL, Wang P, Hu W, Pei G. Chemokine receptor CCR5 functionally couples to inhibitory G proteins and undergoes desensitization. J Cell Biochem. 1998;71:36-45.
14. Dairaghi DJ, Franz-Bacon K, Callas E, et al. Macrophage inflammatory protein-1β induces migration and activation of human thymocytes. Blood. 1998;91:2905-2913.
15. Del Corno M, Liu QH, Schols D, et al. HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxininsensitive chemokine receptor signaling. Blood. 2001;98:2909-2916.
16. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by β-arrestins. Science. 2005;308:512-517.
17. Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol. 2004;36:35-38.
18. Blanpain C, Migeotte I, Lee B, et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood. 1999;94:1899-1905.
19. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol. 2002;14:129-135.
20. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol. 2001;2:102-107.
21. Nieto M, Navarro F, Perez-Villar JJ, et al. Roles of chemokines and receptor polarization in NKtarget cell interactions. J Immunol. 1998;161:3330-3339.
22. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE. Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annu Rev Biochem. 2005;74:385-410.
23. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev. 1999;79:181-213.
24. Wong MM, Fish EN. Chemokines: attractive mediators of the immune response. Semin Immunol. 2003;15:5-14.
25. Molon B, Gri G, Bettella M, et al. T cell costimulation by chemokine receptors. Nat Immunol. 2005;6:465-471.
26. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312:763-767.
27. Jasin M, Page KA, Littman DR. Glycosylphosphatidylinositol-anchored CD4/Thy-1 chimeric molecules serve as human immunodeficiency virus receptors in human, but not mouse, cells and are modulated by gangliosides. J Virol. 1991;65:440-444.
28. Tersmette M, van Dongen JJ, Clapham PR, et al. Human immunodeficiency virus infection studied in CD4-expressing human-murine T-cell hybrids. Virology. 1989;168:267-273.
29. Weiner DB, Huebner K, Williams WV, Greene MI. Human genes other than CD4 facilitate HIV-1 infection of murine cells. Pathobiology. 1991;59:361-371.
30. Cocchi F, DeVico AL, Garzino DA, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270:1811-1815.
31. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272:1955-1958.
32. Arenzana-Seisdedos F, Virelizier JL, Rousset D, et al. HIV blocked by chemokine antagonist. Nature. 1996;383:400.
33. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382:829-833.
34. Choe H, Farzan M, Sun Y, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996;85:1135-1148.
35. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661-666.
36. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381:667-673.
37. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872-877.
38. Unutmaz D, KewalRamani VN, Littman DR. G protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions and on the utility of animal models. Semin Immunol. 1998;10:225-236.
39. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996;384:184-187.
40. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393:648-659.
41. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367-377.
42. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene: Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996;273:1856-1862.
43. Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-Δ32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet. 1998;62:1507-1515.
44. Salkowitz JR, Purvis SF, Meyerson H, et al. Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol. 2001;98:200-211.
45. Gorry PR, Zhang C, Wu S, et al. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Δ32 allele. Lancet. 2002;359:1832-1834.
46. Michael NL, Nelson JA, Kewal Ramani VN, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 Δ32. J Virol. 1998;72:6040-6047.
47. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol. 2006;4:312-317.
48. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
49. Marmor M, Sheppard HW, Donnell D, et al. Homozygous and heterozygous CCR5-Δ32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr. 2001;27:472-481.
50. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Δ32, CCR2-64I, and SDF-13′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 2001;135:782-795.
51. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med. 1997;3:23-36.
52. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993;118:681-688.
53. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621-628.
54. Quillent C, Oberlin E, Braun J, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet. 1998;351:14-18.
55. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005;307:1434-1440.
56. Hummel S, Schmidt D, Kremeyer B, Herrmann B, Oppermann M. Detection of the CCR5-Δ32 HIV resistance gene in Bronze Age skeletons. Genes Immun. 2005;6:371-374.
57. Elvin SJ, Williamson ED, Scott JC, et al. Evolutionary genetics: Ambiguous role of CCR5 in Y. pestis infection. Nature. 2004;430:417.
58. Mecsas J, Franklin G, Kuziel WA, Brubaker RR, Falkow S, Mosier DE. Evolutionary genetics: CCR5 mutation and plague protection. Nature. 2004;427:606.
59. Lalani AS, Masters J, Zeng W, et al. Use of chemokine receptors by poxviruses. Science. 1999;286:1968-1971.
60. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. Science. 2000;288:1789-1796.
61. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet. 2001;357:1758-1761.
62. Akashi S, Sho M, Kashizuka H, et al. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation. 2005;80:378-384.
63. Grone HJ, Weber C, Weber KS, et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J. 1999;13:1371-1383.
64. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203:35-40.
65. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med. 2005;202:1087-1098.
66. Ank N, Petersen K, Malmgaard L, Mogensen SC, Paludan SR. Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2. J Virol. 2005;79:9831-9841.
67. Machado FS, Koyama NS, Carregaro V, et al. CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi. J Infect Dis. 2005;191:627-636.
68. Algood HM, Flynn JL. CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary lymphocytic infiltration. J Immunol. 2004;173:3287-3296.
69. Belnoue E, Kayibanda M, Deschemin JC, et al. CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood. 2003;101:4253-4259.
70. Nansen A, Christensen JP, Andreasen SO, Bartholdy C, Christensen JE, Thomsen AR. The role of CC chemokine receptor 5 in antiviral immunity. Blood. 2002;99:1237-1245.
71. Glass WG, Liu MT, Kuziel WA, Lane TE. Reduced macrophage infiltration and demyelination in mice lacking the chemokine receptor CCR5 following infection with a neurotropic coronavirus. Virology. 2001;288:8-17.
72. Barr EL, Ouburg S, Igietseme JU, et al. Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5Δ32 gene deletion. J Microbiol Immunol Infect. 2005;38:244-254.
73. Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology. 2003;124:352-360.
74. Goulding C, McManus R, Murphy A, et al. The CCR5-Δ32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut. 2005;54:1157-1161.
75. Ahlenstiel G, Woitas RP, Rockstroh J, Spengler U. CC-chemokine receptor 5 (CCR5) in hepatitis C: at the crossroads of the antiviral immune response? J Antimicrob Chemother. 2004;53:895-898.
76. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993;67:6642-6647.
77. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF III, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol. 1994;68:4821-4828.
78. Trkola A, Ketas T, Kewalramani VN, et al. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol. 1998;72:1876-1885.
79. Zwick MB, Labrijn AF, Wang M, et al. Broadly neutralizing antibodies targeted to the membraneproximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol. 2001;75:10892-10905.
80. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005;11:615-622.
81. Husson RN, Chung Y, Mordenti J, et al. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection. J Pediatr. 1992;121:627-633.
82. Schacker T, Coombs RW, Collier AC, et al. The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia. J Infect Dis. 1994;169:37-40.
83. Jacobson JM, Israel RJ, Lowy I, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother. 2004;48:423-429.
84. Wang HG, Williams RE, Lin PF. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding. Curr Pharm Des. 2004;10:1785-1793.
85. Towie N. Drug firms donate compounds for anti-HIV gel. Nature. 2005;438:6-7.
86. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature. 2005;438:99-102.
87. Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol. 2006;6:371-382.
88. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov. 2004;3:215-225.
89. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis. 2005;191:866-872.
90. Hartley O, Gaertner H, Wilken J, et al. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci U S A. 2004;101:16460-16465.
91. Kish-Catalone TM, Lu W, Gallo RC, Devico AL. Preclinical evaluation of synthetic-2 RANTES as a candidate vaginal microbicide to target CCR5. Antimicrob Agents Chemother. 2006;50:1497-1509.
92. Simmons G, Clapham PR, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science. 1997;276:276-279.
93. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science. 2004;306:485-487.
94. Feng Z, Dubyak GR, Lederman MM, Weinberg A. Cutting edge: human beta defensin 3: a novel antagonist of the HIV-1 co-receptor CXCR4. J Immunol. 2006;177:782-786.
95. Quinones-Mateu ME, Lederman MM, Feng Z, et al. Human epithelial β-defensins 2 and 3 inhibit HIV-1 replication. AIDS. 2003;17:F39-F48.
96. Roschke V, Clark S, Branco L, et al. Characterization of a panel of novel human monoclonal antibodies that specifically antagonize CCR5 and block HIV-1 entry. Presented at: 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract 2871.
97. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol. 2005;67:1268-1282.
98. Marozsan AJ, Kuhmann SE, Morgan T, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology. 2005;338:182-199.
99. Westby M, van der Ryst E. CCR5 antagonists: hosttargeted antivirals for the treatment of HIV infection. Antivir Chem Chemother. 2005;16:339-354.
100. GlaxoSmithKline terminates patient enrollment for phase 3 studies of investigational HIV entry inhibitor Aplaviroc (GW873140) [press release]. Research Triangle Park, NC: GlaxoSmithKline; October 25, 2005.
101. Greaves W, Landovitz R, Fatkenheuer G, et al. Late virologic breakthrough in treatment-naïve patients on a regimen of combivir plus vicriviroc. Presented at: XIII Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo. Abstract 161LB.
102. Schering-Plough provides update on phase II study of vicriviroc: study continues in HIV treatment-experienced patients [press release]. Kenilworth, NJ: Schering-Plough Corp; March 3, 2006.
103. Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-Δ32 mutation. Cancer Res. 1999;59:3561-3564.
104. Castagna A, Biswas P, Beretta A, Lazzarin A. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs. 2005;65:879-904.
105. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18:1615-1627.
106. Shelburne SA III, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev. 2003;5:67-79.
107. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749-759.
108. Heise C, Vogel P, Miller CJ, Lackner A, Dandekar S. Distribution of SIV infection in the gastrointestinal tract of rhesus macaques at early and terminal stages of AIDS. J Med Primatol. 1993;22:187-193.
109. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005;434:1093-1097.
110. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;280:427-431.
111. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 2003;17:2015-2023.
112. Valdez H, Smith KY, Landay A, et al; ACTG 375 Team and AIDS Clinical Trials Group. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitorcontaining regimen. AIDS. 2000;14:11-21.
113. Deeks SG. Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients. Lancet. 2006;367:711-713.